Immuno-Oncology

Latest News

kidney cancer
Atezolizumab Falls Short in Pretreated, Advanced Renal Cell Carcinoma

June 17th 2023

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Blood draws © adobe.stock.com
Repeated Hematologic Evaluations May Not be Necessary for Patients Receiving ICIs

June 7th 2023

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS
Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

June 3rd 2023

FDA
Trifluridine/Tipiracil, Plus Bevacizumab Under Priority Review for Refractory mCRC

April 24th 2023

melanoma
mRNA Vaccine, Plus Pembrolizumab, Minimizes Recurrence Rate in Melanoma

April 22nd 2023

Latest CME Events & Activities

Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

The 14th Asia-Pacific Primary Liver Cancer Expert Meeting

July 18 - 20, 2024

Register Now!

Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

View More

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®

View More

Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago

View More

Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC

View More

Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?

View More

2024 International Symposium of Gastrointestinal Oncology (ISGIO)

October 11-12, 2024

Register Now!

Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC

View More

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

More News

© 2024 MJH Life Sciences

All rights reserved.